Strategy
← 실적 발표
01
02
03
04 05 06
톤
A1 A2 A3
INCY
FY2026 Q2
상향
Incyte Corporation 실적 발표
Buzzberg 분석
Company no longer dependent on single asset, multiple growth drivers
Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement.
Buzzberg 분석 Company no longer dependent on single asset, multiple growth drivers Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement. 전체 분석 보기분석 접기
Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement.
- Incyte raised its full-year 2026 total net sales guidance to $5.13-$5.26B.
- The core business (ex-Jakafi) grew 44% YoY, driven by Opzelura, Niktimbo, Monjuvi, and Zynyz.
- Management emphasized a transition away from dependence on a single asset (Jakafi) toward a multi-product, late-stage pipeline.
JAKAFI 매출$0.817B보고값
OPSALURA 매출$0.45B보고값
매출$1.674B+32% 전분기 대비
주당순이익(EPS)$3.09보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Margins
Opsalura CMS settlement improves gross-to-net profile
Pipeline
Latarsabart could be a 'Hemlibra-like' opportunity
핵심 내용 3개 더 보기
Pipeline
989 phase 3 in MF to start after FDA discussions
Pipeline
ESMO data expected to de-risk 734 in pancreatic cancer
Commercial
Jackify XR formulary coverage on track to 50-70%
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| JAKAFI 매출 | $0.817B | 보고값 |
| OPSALURA 매출 | $0.45B | 보고값 |
| 매출 | $1.674B | +32% 전분기 대비 |
| 주당순이익(EPS) | $3.09 | 보고값 |
| 영업이익률 | 41.69% | 보고값 |
| 잉여현금흐름 | $0.4952B | +38% 전분기 대비 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 영업이익률 | FY2026 | $4.915B–$4.995B | $4.955B | 상향 |
| 영업이익률TOTAL_NON_GAAP | FY2026 | $4.625B–$4.695B | $4.66B | 상향 |
| 매출 | FY2026 | $5.13B–$5.26B | $5.195B | 상향 |
| 매출OPSALURA | FY2026 | $1.05B–$1.1B | $1.075B | 상향 |
| 매출HEMATOLOGY_ONCOLOGY | FY2026 | $0.86B–$0.89B | $0.875B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed strong confidence in the company's transition, execution, and pipeline progress, repeatedly emphasizing tangible achievements and a positive outlook.
아래에 언급된 기업 5개 모두 표시
기업발표 이후 수익률
파트너
파트너
Suki
Novartis's settlement with Incyte reduced Incyte's expense base in the prior year, indicating a financial relationship between the companies.
근거
“The year-over-year increase reflects a lower expense base in the second quarter of 2025, resulting from the Novartis settlement of $242 million.”
파트너
Pablo
Syndax is running the Niktimbo IPF study; its data readout will be a key catalyst for a potential opt-in decision by Incyte.
근거
“The disclosure of the data, since they're conducting the study, will be done by Syndex.”
파트너
Pablo
Collaborating with Halozyme to optimize the subcutaneous formulation of 9A9 using their enhanced delivery technology adds optionality and could improve patient experience for the drug.
근거
“We recently entered a global collaboration and license agreement with Halozyme to evaluate the subcutaneous formulation of 9A9 using enhanced technology.”
파트너
Pablo
Incyte has a collaboration with Prelude for JAK2V617F assets, but owns the decision on whether to opt in based on data coming from Prelude.
근거
“On the Prelude Agreement, obviously those programs are managed by Prelude.”
공급망
공급망
Bill
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting. — With a third of the market, Incyte faces direct competition from Gilead's momelotinib and possibly others; maintaining this share is key to the heme-onc portfolio's growth.
근거
“We currently hold approximately one third of the third line plus market.”
외부 신호
공급망 알파 · 3발표 이후 수익률
Incyte's 989 MPN program may use a differentiated regulatory path with the FDA that could include novel efficacy endpoints like hemoglobin improvement, potentially setting a new precedent for MPN trials.
근거
“We thought and still think it's important to have a constructive dialogue with the FDA to see how we can incorporate some of these endpoints that reflect the benefit patients receive from 9A9.”
Incyte discontinuing 058 highlights increased risk in the JAK2V617F inhibitor space, but they signal a next-gen program with better data is advancing toward the clinic.
근거
“We decided to discontinue development 058, our lead asset in our JAK2V617F targeted pipeline, and are no longer expecting to report data later this year. ... The next generation programs have moved along very, very well.”
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 5개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.